neurology

News

Bayer reveals data behind asundexian's stroke win

Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial.

R&D

Organoid neurotoxicity testing gains momentum

Organoid-based approaches may become an integral part of neurological safety testing, offering a clearer view of risk.

Digital

pharmaphorum podcast Episode 236, Tarek Samad, Lundbeck

An AI supercomputer and discovering next-gen brain disorder ...

Tarek Samad, Lundbeck’s senior vice president and head of research, discusses AI – specifically, Lundbeck’s agreement with the DCAI to operate Gefion.

R&D

Q4 Clinical trials round-up: October to December 2025

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.

News

FDA clears trial of 'vectorised' ALS antibody from VectorY

VectorY has been cleared by the FDA to start human trials of a drug against a target implicated in up to 97% of amyotrophic lateral sclerosis cases.

News

Disappointment as Novo's oral GLP-1 fails in Alzheimer's

GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer's disease may not be among them.

Bayer reveals data behind asundexian's stroke win

Organoid neurotoxicity testing gains momentum

An AI supercomputer and discovering next-gen brain disorder ...

Q4 Clinical trials round-up: October to December 2025

FDA clears trial of 'vectorised' ALS antibody from VectorY

Disappointment as Novo's oral GLP-1 fails in Alzheimer's

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

neurology

Editor's Picks